Central nervous system (CNS) infections are common across all ages in Sub-Saharan Africa in people with or without HIV-infection. In persons with HIV, cryptococcal meningitis has historically been the second most common AIDS-defining illness in Africa and the most common cause of adult meningitis in Sub-Saharan Africa overall. The next most common cause of meningitis is likely TB meningitis, although CSF diagnostics are challenging. With the widespread availability of antiretroviral therapy (ART), long term survival in persons living with AIDS and CNS infections should be possible, but delayed or inaccurate diagnoses and limited therapeutic options contribute to poor outcomes. Furthermore, with the ?test and treat? strategy of immediate ART initiation, more people are presenting with CNS infections unmasked after starting ART, yet their outcomes are unclear. We propose to continue a prospective cohort study of 1200 new HIV-infected persons presenting with suspected CNS infection in Kampala and Mbarara, Uganda. We will use point-of-care and molecular diagnostics to rapidly determine the etiologies of CNS infections, with a specific focus on optimizing and validating new diagnostic tests, such as a semi-quantitative cryptococcal antigen (CrAg-SQ) lateral flow assay and the Xpert MTB/RIF Ultra for TB meningitis. Second, we propose to conduct phase II trial investigating the microbiologic effects of a novel oral antifungal agent (APX001) that inhibits fungal GWT1 enzyme blocking fungal mannoprotein transport to the cell wall surface and is synergistic with fluconazole. Finally, we will measure neurocognitive performance to investigate the effect of recent ART initiation on neurologic outcomes.
Specific Aims 1. Determine the etiology of CNS infections in Sub-Saharan Africa among HIV-infected adults through use of a stepwise diagnostic algorithm coupled with next-generation sequencing and post-mortem exams. 2. Determine in HIV-related cryptococcal meningitis if oral APX001, a novel fungal GWT1 (GPI-anchored wall transport protein 1) inhibitor, achieves with concomitant fluconazole a non-inferior rate of CSF Cryptococcus clearance as compared with IV amphotericin B deoxycholate and fluconazole. 3. Determine if neurocognitive outcomes in HIV-infected persons presenting with CNS infections unmasked after recent ART initiation are worse than in ART-nave persons presenting with CNS infections. Hypotheses: 1. We hypothesize in the ART era that cryptococcal and TB meningitis remain the two most common etiologies of meningitis in an HIV-infected population despite the ?test and treat? ART strategy. 2. We hypothesize that APX001, a novel broad spectrum oral antifungal agent is well tolerated and will have a non-inferior rate of CSF sterilization compared with IV amphotericin B in cryptococcal meningitis. 3. We hypothesize neurocognitive outcomes are worse in CNS infections unmasked on ART vs. ART-nave.

Public Health Relevance

Meningitis is the second most common AIDS defining illness in Sub-Saharan Africa causing approx. 15-20% of the AIDS-attributable mortality in Africa. Overall Cryptococcus and TB are the two most common causes of meningitis in Sub-Saharan Africa; however, a significant number of brain infections are of unknown etiology. This project seeks to test new diagnostics and new innovative oral therapies for fungal meningitis in order to improve survival and neurologic outcomes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS086312-06A1
Application #
9827929
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Wong, May
Project Start
2013-09-01
Project End
2024-04-30
Budget Start
2019-07-15
Budget End
2020-04-30
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Ellis, Jayne; Cresswell, Fiona V; Joshua, Rhein et al. (2018) Cryptococcal Meningitis and Tuberculous Meningitis Co-infection in HIV-Infected Ugandan Adults. Open Forum Infect Dis 5:ofy193
Bahr, Nathan C; Lee, Deborah; Stauffer, William M et al. (2018) Seroprevalence of Histoplasmosis in Somali, Burmese, and Hmong Refugees Residing in Thailand and Kenya. J Immigr Minor Health 20:334-338
Kajumbula, Henry; Fujita, Ayako Wendy; Mbabazi, Olive et al. (2018) Antimicrobial Drug Resistance in Blood Culture Isolates at a Tertiary Hospital, Uganda. Emerg Infect Dis 24:174-175
Atherton, Rachel R; Cresswell, Fiona V; Ellis, Jayne et al. (2018) Detection of Mycobacterium tuberculosis in urine by Xpert MTB/RIF Ultra: A useful adjunctive diagnostic tool in HIV-associated tuberculosis. Int J Infect Dis 75:92-94
Kwizera, Richard; Akampurira, Andrew; Kandole, Tadeo K et al. (2018) Evaluation of trypan blue stain in the TC20 automated cell counter as a point-of-care for the enumeration of viable cryptococcal cells in cerebrospinal fluid. Med Mycol 56:559-564
Mpoza, Edward; Mukaremera, Liliane; Kundura, Didas Atwebembere et al. (2018) Evaluation of a point-of-care immunoassay test kit 'StrongStep' for cryptococcal antigen detection. PLoS One 13:e0190652
Mpoza, Edward; Rhein, Joshua; Abassi, Mahsa (2018) Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis. Med Mycol Case Rep 19:30-32
Bahr, Nathan C; Boulware, David R; Cresswell, Fiona V (2018) Xpert Ultra's place in the diagnosis of tuberculous meningitis - Authors' reply. Lancet Infect Dis 18:249-250
Rajasingham, R; Meya, D B; Boulware, D R (2018) Are fluconazole or sertraline dose adjustments necessary with concomitant rifampin? HIV Med 19:e64-e65
Diehl, John W; Hullsiek, Katherine H; Okirwoth, Michael et al. (2018) Cerebral Oximetry for Detecting High-mortality Risk Patients with Cryptococcal Meningitis. Open Forum Infect Dis 5:ofy105

Showing the most recent 10 out of 44 publications